Saiga, Rino
Uesugi, Masayuki
Takeuchi, Akihisa
Uesugi, Kentaro
Suzuki, Yoshio
Takekoshi, Susumu
Inomoto, Chie
Nakamura, Naoya
Torii, Youta
Kushima, Itaru
Iritani, Shuji
Ozaki, Norio
Oshima, Kenichi
Itokawa, Masanari
Arai, Makoto
Mizutani, Ryuta
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP19dm0107108, JP20dm0107087, JP20dm0207075, JP20dk0307081, JP20ak0101113, JP18dm0107088, JP19dm0107088, JP20dm0107088)
Japan Society for the Promotion of Science (18H04040, 20H03608, 21611009, 25282250, 25610126)
Article History
Received: 14 February 2021
Accepted: 25 May 2021
First Online: 3 June 2021
Competing interests
: M.I. and M.A. declare a conflict of interest, being authors of several patents regarding therapeutic use of pyridoxamine for schizophrenia. All other authors declare no competing interests.